InvestorsHub Logo
Followers 18
Posts 1427
Boards Moderated 0
Alias Born 11/01/2018

Re: None

Saturday, 12/21/2019 11:11:05 AM

Saturday, December 21, 2019 11:11:05 AM

Post# of 458727
A couple of weeks ago CTAD data show that A2-73 score from baseline at week 104 of matched cohorts was assessed. It showed that ANAVEX®2-73 (blarcamesine) high dose cohort had a significantly lower MMSE decline (-1.1) compared to the ADNI control cohort (-4.4) at week 104 (p < 0.01).

This is currently the best drug results for CNS disease out there. This is proof that it works and should be the new standard of care drug.IMO. Name another drug that beats it?


https://finance.yahoo.com/news/anavex-life-sciences-presents-anavex-120010950.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News